Acute effects of 3, 4-methylenedioxymethamphetamine (MDMA) on behavioral measures of impulsivity: alone and in combination with alcohol

Ramaekers and colleagues situate their study in the context of mixed findings about impulsivity among MDMA users. Earlier research described both decreased and increased impulsivity in abstinent MDMA users depending on the measures used, and biological work has linked elevated impulsiveness to low serotonin (5-HT) markers and to dopaminergic activation in prefrontal regions. The authors note that most prior MDMA research used self-report instruments and studies in abstinent users, and argue that acute, placebo-controlled studies using behavioural tasks are needed to establish a direct pharmacological relation between MDMA intoxication and impulse control. The present study therefore set out to assess the acute effects of MDMA, and of MDMA combined with alcohol, on behavioural measures of impulsivity and risk-taking. Using a double-blind, placebo-controlled within-subject design, the investigators tested rapid motor inhibition (stop-signal and go/no-go tasks) and decision-making under uncertainty (Iowa gambling task). They hypothesised that acute increases in brain serotonin after a single MDMA dose would improve impulse control, and included alcohol both as an active control (given its known impairing effects on inhibition) and to test for MDMA by alcohol interactions.

The study used a double-blind, placebo-controlled six-way crossover design. Eighteen recreational MDMA users (nine males, nine females), aged 20–37 years, participated; they reported light-to-moderate recent MDMA use (2–25 occasions in the previous year, mean about 9 occasions). Inclusion criteria included prior MDMA experience, absence of psychotropic medication and major medical or neurological disorders, normal weight/BMI reported between 18 and 28 kg/m2, and written informed consent. Exclusion criteria included a history of drug abuse (other than MDMA), pregnancy or lactation, cardiovascular abnormalities on ECG, excessive drinking (the extracted text gives a threshold but it is not clearly reported), hypertension (thresholds are reported in the extracted text but not clearly readable), and psychiatric or neurological disorder. Screening included medical history, vitals, blood and urine drug screens and standard blood chemistry. Subjects received a training session on the tasks before experimental sessions. Each participant completed six treatment sessions in randomised order with a minimum 1-week washout. Treatments were oral MDMA at 0, 75 and 100 mg, each given with and without alcohol. MDMA was administered as a 25 ml solution in bitter orange peel syrup. Alcohol was dosed to target a peak blood alcohol concentration (BAC) of about 0.06 g/dl, administered 45 min after MDMA and consumed within 15 min. Laboratory testing occurred between 1.5 and 2 h after MDMA administration (that is, approximately 0.5–1 h after alcohol). BAC was monitored every 15 min for 30–90 min after drinking using a Lion SD-4 Breath Alcohol Analyser. Blood for MDMA and MDA quantification was taken at 1.5 h post drug and stored for gas chromatography–mass spectrometry analysis. Behavioural endpoints comprised three established tasks. The stop-signal task measured ability to inhibit an initiated motor response; dependent variables were proportion of commission errors on stop trials and stop reaction time (an estimate of the time required to inhibit a response, calculated using the race model). The go/no-go task measured suppression of a habitual response, with dependent variables of mean reaction time on go trials and commission errors on no-go trials; signal detection theory was applied to derive sensitivity (d') and response criterion (b). The Iowa gambling task assessed decision-making under uncertainty, with net score (cards chosen from advantageous minus disadvantageous decks) as the outcome. Pharmacokinetic measures included plasma MDMA and MDA concentrations and serial BACs. Statistical analyses used repeated measures MANOVA with factors MDMA (three levels) and alcohol (two levels) and their interaction; drug–placebo contrasts were performed after overall effects. The alpha level was set at p = 0.05.

Eighteen complete data sets were available for the Iowa gambling and go/no-go tasks; one stop-signal data set was incomplete due to technical problems and excluded. On the stop-signal task, repeated measures MANOVA showed a significant overall main effect of MDMA on stop reaction time (F2,15 = 4.62; p = 0.027), reflecting shorter stop reaction times (improved inhibitory speed) under MDMA relative to placebo. The MDMA 75 mg dose produced a particularly notable effect in drug–placebo contrasts (p = 0.008). MDMA did not significantly change the proportion of commission errors in the stop-signal task. Alcohol produced significant impairments on motor inhibition measures. MANOVA indicated main effects of alcohol on the percentage of commission errors in the stop-signal task (F1,16 = 7.06; p = 0.017) and in the go/no-go task (F1,17 = 7.84; p = 0.012), with higher proportions of commission errors during alcohol treatments. Signal detection analysis of the go/no-go task showed that alcohol reduced sensitivity (d') to discriminate go from no-go signals (F1,17 = 18.25; p = 0.001) but did not alter response criterion (b), suggesting impaired perceptual or attentive processing rather than a liberal shift in response bias. Reaction times on go and no-go trials were not significantly affected by alcohol. In the Iowa gambling task, MDMA did not affect performance. Alcohol showed a trend toward improved performance (higher net scores), with a near-significant main effect (F1,17 = 3.14; p = 0.09), indicating a tendency to select more advantageous cards under alcohol, although this did not reach the study's significance threshold. No significant MDMA × alcohol interactions were found for any behavioural measure. Pharmacokinetic data reported that mean BACs did not significantly differ between treatments. The extracted values for mean (SE) BACs at the onset of laboratory testing (30 min post drinking) were 0.65 (0.19), 0.56 (0.12), and 0.57 (0.16) mg/ml following placebo, MDMA 75 mg and MDMA 100 mg, respectively; at the end of testing (60 min post drinking) the values were 0.64 (0.16), 0.59 (0.11) and 0.59 (0.12) mg/ml for the same conditions. Plasma MDMA concentrations at 1.5 h post drug averaged 137.4 (31.9) ng/ml and 191.8 (49.1) ng/ml after 75 and 100 mg doses, respectively; combinations with alcohol produced similar or slightly higher concentrations. MDA concentrations were low and comparable across conditions.

Ramaekers and colleagues interpret their findings as showing that a single acute dose of MDMA can improve inhibitory motor control, as evidenced by reduced stop reaction time in the stop-signal task, while a moderate dose of alcohol impairs the ability to inhibit responses in rapid-response paradigms. They emphasise that this is the first controlled study to assess acute MDMA effects on behavioural measures of impulsivity. The investigators propose two plausible pharmacological mechanisms for the MDMA effect: acute serotonergic ‘‘suppletion’’ (MDMA increases 5-HT release and blocks reuptake) and augmented dopaminergic neurotransmission, either of which could plausibly speed inhibitory processing. They place this acute improvement in the context of studies showing low serotonergic markers and impaired impulse control in abstinent MDMA users, suggesting that impulsivity may decrease during acute MDMA intoxication but increase during abstinence when serotonin markers are diminished. The authors also note that the study sample (light-to-moderate recreational users) may respond more like healthy volunteers than long-term stimulant abusers, and they reference prior work showing that chronic stimulant exposure can alter responses to acute dopaminergic stimulation. A central interpretive point concerns the dissociation between motor and cognitive impulsivity: MDMA selectively improved motor inhibition (stop-signal) while leaving cognitive decision-making (Iowa gambling task) unchanged. The authors link this to the notion that impulsivity is multi-dimensional and mediated by distinct neural substrates (for example, anterior cingulate involvement in motor inhibition versus ventromedial prefrontal cortex in decision-making). Regarding alcohol, the team argues that increased commission errors under alcohol reflected reduced sensory/attentional sensitivity rather than a shift toward riskier response bias, because d' decreased while response criterion did not change and reaction times were unaffected. They acknowledge that the go/no-go task was relatively easy for participants and recommend increasing task difficulty in future work to probe sensitivity and criterion effects further. No MDMA by alcohol interactions were observed, leading the authors to conclude that MDMA's central stimulating effects do not overcome alcohol-induced impairment of motor control. They note that this aligns with earlier work showing that MDMA reverses alcohol-induced subjective sedation but does not mitigate alcohol-related psychomotor impairment. As an applied implication, the investigators highlight road-safety concerns: users combining MDMA and alcohol may experience alcohol-induced loss of motor control despite subjective stimulation from MDMA. The authors discuss sample characteristics and task-specific considerations as relevant limitations, and they frame the results as prompting further research into distinct impulsivity domains and the acute versus chronic effects of MDMA on inhibitory control.